---
title: "Metagenomi Therapeutics, Inc. (MGX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/MGX.US.md"
symbol: "MGX.US"
name: "Metagenomi Therapeutics, Inc."
industry: "Biotechnology"
---

# Metagenomi Therapeutics, Inc. (MGX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [metagenomi.co](https://metagenomi.co) |

## Company Profile

Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, an...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-25T04:30:15.000Z

**Overall: D (0.74)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 293 / 401 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -43.88% |  |
| Net Profit YoY | -19.99% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.32 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 56.32M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 30.91M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -40.87% | E |
| Profit Margin | -287.06% | E |
| Gross Margin | -191.99% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -43.88% | E |
| Net Profit YoY | -19.99% | D |
| Total Assets YoY | -30.81% | E |
| Net Assets YoY | -30.23% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -34.84% | D |
| OCF YoY | -43.88% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.10 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 28.03% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Metagenomi Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-40.87%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-287.06%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-191.99%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-43.88%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-19.99%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-30.81%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-30.23%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-34.84%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-43.88%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "28.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Vertex Pharma (US.VRTX) | A | B | C | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.63 | 155/604 | - | - | - |
| PB | 0.32 | 19/604 | 0.40 | 0.34 | 0.27 |
| PS (TTM) | 1.82 | 46/604 | 2.13 | 1.87 | 1.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 80% |
| Overweight | 0 | 0% |
| Hold | 1 | 20% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.52 |
| Highest Target | 12.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/MGX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/MGX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/MGX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.